Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)

Inclusion Criteria: 1. Patients with haematological malignancies, according to WHO classification, such as: * acute myeloid leukaemia -AML- in CR1 except "low-risk cases" defined by t(15;17), t(8;21), inv 16 or normal cytogenetics at diagnosis with FLT3-ITD negative and NPM-1 positive, with no high risk clinical criteria * any AML beyond CR1 * acute lymphoblast leukaemia -ALL- in CR1 only if at "high risk" defined by cytogenetics as t(9;22), t(4;11) or for persistence of minimal residual disease (MRD) * any ALL beyond CR1 * chronic myeloid leukaemia -CML- in chronic phase (CP) or accelerated phase (AP) intolerant/not responsive to TK-inhibitors * myeloproliferative disorders -MPD- * myelodysplastic syndrome -MDS- with intermediate or high risk International Prognostic Scoring System (IPSS) * diffuse large cell lymphoma -DLCL- with a chemosensitive relapse or beyond CR1 * lymphoblastic and Burkitt lymphoma with a chemosensitive relapse or beyond CR1 * mantle cell lymphoma -MCL- with a chemosensitive relapse or beyond CR1 * follicular lymphoma -FCL- with a chemosensitive relapse or beyond CR2 * Hodgkin lymphoma -HD- with a chemosensitive relapse or beyond CR1 * chronic lymphocytic leukaemia -CLL- at "poor risk" in CR1 or with a chemosensitive relapse * CLL relapsing after high dose chemotherapy * T-cell non Hodgkin lymphoma -T-NHL- in CR1 or beyond * multiple myeloma -MM- at high risk for cytogenetics or ISS stage 3 in CR1 following high dose chemotherapy * MM at any relapse/progression except refractory disease 2. Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor (MUD) * HLA-identity defined by the following markers: A, B, DRB1, DQB1 or a single or double Cord Blood unit (CB) with at least a 4 out of 6 HLA-matching by the following markers: A, B and DRB. A) identity between the 2 CB units and the recipient; B) Two identical CB units with one or two mismatches with the recipient; C) Two CB units with one mismatch between them and two mismatches with the recipient. We will prefer mismatches either for class I or for class II antigens; we will avoid mismatches concerning both classes I and II together. 3. Target graft size (unmanipulated, preferably not cryopreserved) * bone marrow: 2 to 10 x 106 CD34+ cells/kg BW recipient or \> 2 x 108 nucleated cells/kg BW recipient or * peripheral blood: 4 to 10 x 106 CD34+ cells/kg BW recipient 4. Age \> 18 and \< 70 years 5. Karnofsky Index \> 80 % 6. Adequate contraception in female patients of child-bearing potential 7. Written informed consent Exclusion Criteria: 1. Secondary malignancies 2. Previous allogeneic transplantation 3. Hematopoietic cell transplantation-specific comorbidity index \> 4 (HCT-CI Sorror et al, Appendix M) 4. Known and manifested malignant involvement of the CNS 5. Active infectious disease 6. HIV- positivity or active hepatitis infection 7. Impaired liver function (Bilirubin \> upper normal limit; Transaminases \> 3.0 x upper normal limit) 8. Impaired renal function (Creatinine-clearance \< 60 ml/min; Serum Creatinine \> 1.5 x upper normal limit). 9. Pleural effusion or ascites \> 1.0 L 10. Pregnancy or lactation 11. Known hypersensitivity to treosulfan and/or fludarabine 12. Participation in another experimental drug trial within 4 weeks before day -6 13. Non-co-operative behaviour or non-compliance 14. Psychiatric diseases or conditions that might impair the ability to give informed consent